BI
ELDN icon

BVF Inc’s Eledon Pharmaceuticals ELDN Stock Holding History

BVF Inc’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.8M Hold
6,293,282
– – 0.63% 31
2026
Q1 		$19.4M Hold
6,293,282
– – 0.62% 31
2025
Q4 		$9.5M Hold
6,293,282
– – 0.32% 32
2025
Q3 		$16.3M Hold
6,293,282
– – 0.66% 33
2025
Q2 		$17.1M Hold
6,293,282
– – 0.61% 26
2025
Q1 		$21.3M Hold
6,293,282
– – 0.87% 22
2024
Q4 		$25.9M Hold
6,293,282
– – 0.88% 24
2024
Q3 		$15.7M Hold
6,293,282
– – 0.46% 31
2024
Q2 		$16.6M Buy
6,293,282
+1,966,572
+45% +$4.69M 0.47% 36
2024
Q1 		$8.91M Hold
4,326,710
– – 0.25% 41
2023
Q4 		$7.79M Hold
4,326,710
– – 0.19% 51
2023
Q3 		$5.93M Hold
4,326,710
– – 0.16% 53
2023
Q2 		$5.93M Buy
4,326,710
+2,000,000
+86% +$4.17M 0.17% 52
2023
Q1 		$5.49M Hold
2,326,710
– – 0.2% 57
2022
Q4 		$5.4M Hold
2,326,710
– – 0.23% 56
2022
Q3 		$6.42M Hold
2,326,710
– – 0.27% 57
2022
Q2 		$5.68M Hold
2,326,710
– – 0.27% 57
2022
Q1 		$9.17M Buy
2,326,710
+948,690
+69% +$3.68M 0.37% 57
2021
Q4 		$6.08M Buy
1,378,020
+14,585
+1% +$73.8K 0.22% 62
2021
Q3 		$8.43M Buy
1,363,435
+250,000
+22% +$1.75M 0.33% 58
2021
Q2 		$8.81M Hold
1,113,435
– – 0.33% 52
2021
Q1 		$11.9M Buy
1,113,435
+350,156
+46% +$5.28M 0.45% 45
2020
Q4 		$11.8M Buy
763,279
+567,953
+291% +$10.8M 0.46% 40
2020
Q3 		$3.34M Buy
195,326
+96,159
+97% +$947K 0.18% 57
2020
Q2 		$818K Buy
99,167
+61,122
+161% +$690K 0.05% 55
2020
Q1 		$267K Sell
38,045
-8,004
-17% -$76.5K 0.02% 57
2019
Q4 		$481K Hold
46,049
– – 0.04% 56
2019
Q3 		$522K Hold
46,049
– – 0.05% 59
2019
Q2 		$837K Buy
+46,049
New +$2.01M 0.09% 56

Other funds holding ELDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

BVF Inc's ELDN Position: Q2 2026 in Review

BVF Inc held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2026 at 6,293,282 shares worth $24.8M. The position accounts for 0.63% of the portfolio, ranked #31.

BVF Inc first reported a position in ELDN in Q2 2019 and has held it in 29 quarters since. The position peaked at $25.9M in Q4 2024. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • BVF Inc held 6,293,282 shares of Eledon Pharmaceuticals worth $24.8M as of Q2 2026.
  • BVF Inc left its Eledon Pharmaceuticals share count unchanged in Q2 2026.
  • Eledon Pharmaceuticals made up 0.63% of BVF Inc's portfolio in Q2 2026, its #31 holding.
  • BVF Inc first reported a position in Eledon Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • BVF Inc's Eledon Pharmaceuticals position peaked at $25.9M in Q4 2024.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on BVF Inc's 13F filing for Q2 2026, filed 14 Aug 2026.